Prothena Presents New Preclinical Data Supporting Best-In-Class Profile Of PRX012, A Next-Generation Anti-Amyloid Beta Antibody, At AD/PD 2023
Data from oral presentation adds to growing body of evidence supporting the profile of PRX012, which is designed to target all aggregated forms of amyloid beta with high binding potency
Demonstrated 20-fold higher
